A Phase 2 interventional study of JNJ-42847922 and Placebo Matching to JNJ-42847922 in Depressive Disorder, Major, sponsored by Janssen Research & Development, LLC. Completed at 50 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-04-29.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing seltorexant in Depressive Disorder, Major — 2 open to participants now, 2 under way, 2 of them phase 3. seltorexant · Depressive Disorder, Major.
Among the 12 studies testing seltorexant in Depressive Disorder, Major, this one is the 8th largest by enrollment, is one of 2 that started in 2017, is one of 2 in phase 2, and was the 4th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →2 of the 12 studies testing seltorexant in Depressive Disorder, Major are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States, Argentina, Brazil and 4 more countries
Ages 18–74
Janssen Research & Development, LLC · Sites in United States, Argentina, Brazil and 13 more countries
Ages 18–74
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 107 is above the median of 79 across 2,533 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 176 across the 12 interventional studies. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 2 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
59 studies in Depressive Disorder, Major by Johnson & Johnson: 5 open now, 5 under way, 5 of them phase 3. Of 53 finished, 26 (49%) have results posted.
Among the 59 studies in Depressive Disorder, Major by Johnson & Johnson, this one is the 35th largest by enrollment of the 52 interventional ones that give a count, is one of 5 that started in 2017, is one of 17 in phase 2, and was the 29th registered.
Johnson & Johnson’s Depressive Disorder, Major studies by the year they started, since 2002.
1 of the studies testing seltorexant in Depressive Disorder, Major that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559306Phase 3Janssen Research & Development, LLCPhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | 2026-12-30 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing seltorexant in Depressive Disorder, Major, from their registry updates:
Among Johnson & Johnson’s 59 in Depressive Disorder, Major:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy of flexibly dosed JNJ-42847922 (20 milligram [mg] or 40 mg) compared to flexibly dosed quetiapine extended-release (XR) (150 mg or 300 mg) as adjunctive therapy to an antidepressant drug in delaying time to all-cause discontinuation of study drug over a 6-months (24 weeks) treatment period, in participants with major depressive disorder (MDD) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 20 mg of JNJ-42847922 as a starting dose and matching placebo (1 capsule of 20 mg JNJ-42847922 and 1 capsule of matching placebo) once daily for 14 days. After Day 14, if needed, JNJ-42847922 dose can be increased to 40 mg (2\*20 mg capsules) and flexible dose of JNJ-42847922 (20 or 40 mg) will be taken once daily until Day 167. Dose of JNJ-42847922 (20 or 40 mg) will be adjusted by investigator based on the participant's clinical response and tolerability. Participants will continue to take their baseline selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases.
Drug: JNJ-42847922 · Drug: Placebo Matching to JNJ-42847922 · Drug: Selective Serotonin Reuptake Inhibitor (SSRI) · Drug: Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Participants will receive 1 capsule of quetiapine XR 50 mg along with 1 capsule of matching placebo once daily for 2 days, followed by 1 capsule of quetiapine XR 150 mg along with 1 capsule of matching placebo once daily from Day 3 to Day 14. After Day 14, if needed, quetiapine XR dose can be increased to 300 mg (2\*150 mg capsules) and flexible dose of quetiapine (150 or 300 mg) will be taken once daily until Day 167. Dose of quetiapine XR (150 or 300 mg) will be adjusted by investigator based on the participant's clinical response and tolerability. Participants will continue to take their baseline SSRI/SNRI antidepressant as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases.
Drug: Quetiapine XR · Drug: Placebo Matching to Quetiapine XR · Drug: Selective Serotonin Reuptake Inhibitor (SSRI) · Drug: Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Participants will receive JNJ-42847922 capsule orally.
Also known as: MIN-202;, Seltorexant
Participants will receive placebo capsule matching to JNJ-42847922 orally.
Participants will receive quetiapine XR capsule orally.
Participants will receive placebo capsule matching to quetiapine XR orally.
Participants will receive SSRI antidepressant (such as, citalopram, escitalopram, fluvoxamine, fluoxetine, paroxetine, sertraline, vilazodone or vortioxetine) as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases (approximately up to Week 26).
Participants will receive SNRI antidepressant (such as duloxetine, milnacipran, levomilnacipran, venlafaxine, desvenlafaxine) as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases (approximately up to Week 26).
Time to All-Cause Discontinuation of Study Drug
Time to all-cause discontinuation of study drug is defined as the number of days from the first dose of study drug to the last dose of study drug. Participants who completed double-blind treatment were not considered to have discontinued.
Time frame: Up to Week 24
Percentage of Participants With Sustained Remission up to Week 24
Remission is defined as Montgomery-Asberg Depression Rating Scale (MADRS) total score of less than or equal to (\<=) 12. A participant was defined as having achieved sustained remission if the MADRS total score was ≤12 at Week 12 and was sustained at Weeks 18 and 24. Participants with missing values at a given time point were imputed as non-evaluable for remission. MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition.
Time frame: Up to Week 24
Percentage of Participants With Sustained Response up to Week 24
A participant was defined as having achieved a sustained response if there was at least a 50% improvement from baseline in the MADRS total score at Week 12, and that response was maintained at Week 18 and Week 24. Participants who did not meet such criterion were considered as non-sustained responders. MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition.
Time frame: Up to Week 24
Change From Baseline in MADRS Total Score in Participants With Significant Insomnia (Baseline Insomnia Severity Index [ISI] Score >=15) Versus Those Without Significant Insomnia (Baseline ISI Score Less Than [<] 15) at Week 12
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. The ISI has 7 questions, each rated on a 5-point Likert scale ranging from 0 to 4. The total score is calculated as the sum of the 7 items ranging from 0 to 28. Higher scores represent a more severe condition.
Time frame: Baseline and Week 12
Change From Baseline in MADRS Total Score in Participants With Significant Insomnia (Baseline ISI Score >=15) Versus Those Without Significant Insomnia (Baseline ISI Score <15) at Week 18
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. The ISI has 7 questions, each rated on a 5-point Likert scale ranging from 0 to 4. The total score is calculated as the sum of the 7 items ranging from 0 to 28. Higher scores represent a more severe condition.
Time frame: Baseline and Week 18
Change From Baseline in MADRS Total Score in Participants With Significant Insomnia (Baseline ISIscore >=15) Versus Those Without Significant Insomnia (Baseline ISI Score 15) at Week 24
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. The ISI has 7 questions, each rated on a 5-point Likert scale ranging from 0 to 4. The total score is calculated as the sum of the 7 items ranging from 0 to 28. Higher scores represent a more severe condition.
Time frame: Baseline and Week 24
Change From Baseline in the Hamilton Anxiety Rating Scale (HAM-A) Total Score at Weeks 12, 18, and 24
HAM-A is a 14-item scale designed to measure anxiety in individuals. Each question reflects a symptom of anxiety and physical as well as mental symptoms are represented. Each of the 14-items in the scale is scored on a 5-point scale, ranging from 0 (a complete lack of that symptom) to 4 (a very severe show of anxiety with that symptom). The total score ranges from 0 to 56 which is calculated by adding the scores of all 14 items, where 0-13 indicates normal range, 14-17 indicates mild severity, 18 -24: mild to moderate severity, 25 -30: moderate to severe, and \>=31: severe. Higher score indicates worsening. Negative change in score indicates improvement.
Time frame: Baseline, Weeks 12, 18, and 24
Percentage of Participants With Weight Gain of >=7% of Baseline Body Weight at Week 24
Percentage of participants with weight gain of \>=7% of baseline body weight at Week 24 were reported.
Time frame: At Week 24
Percentage of Participants With Shifts in Triglycerides From Normal to High
Percentage of participants with shifts in triglycerides from normal to high (\<150 milligrams per deciliter \[mg/dL\] at baseline to \>=200 mg/dL at any post-baseline assessment) were reported.
Time frame: Up to Week 24
Percentage of Participants With Shifts in Triglycerides From Borderline to High
Percentage of participants with shifts in triglycerides from borderline to high (\>=150 to \<200 mg/dL at baseline to \>=200 mg/dL at any post-baseline assessment) were reported.
Time frame: Up to Week 24
Percentage of Participants With Shifts in Triglycerides From Normal to Very High
Percentage of participants with shifts in triglycerides from normal to very high (\<150 mg/dL at baseline to \>=500 mg/dL at any post-baseline assessment) were reported.
Time frame: Up to Week 24
Percentage of Participants With Shifts in Triglycerides From Borderline to Very High
Percentage of participants with shifts in triglycerides from borderline to very high (\>=150 mg/dL to \<200 mg/dL at baseline to \>=500 mg/dL at any post-baseline assessment) were reported.
Time frame: Up to Week 24
Percentage of Participants With Shifts in Triglycerides From High to Very High
Percentage of participants with shifts in triglycerides from high to very high (\>=200 mg/dL to \<500 mg/dL at baseline to \>=500 mg/dL at any post-baseline assessment) were reported.
Time frame: Up to Week 24
Percentage of Participants With Shifts in Fasting Blood Glucose From Normal to Borderline
Percentage of participants with shifts in fasting blood glucose from normal to borderline (\<100 mg/dL at baseline to between \>=100 and \<126 mg/dL at any post-baseline assessment) were reported.
Time frame: Up to Week 24
Percentage of Participants With Shifts in Fasting Blood Glucose From Borderline to High
Percentage of participants with shifts in fasting blood glucose from borderline to high (\>=100 to \<126 mg/dL at baseline to \>=126 mg/dL at any post-baseline assessment) were reported.
Time frame: Up to Week 24
Percentage of Participants With Shifts in Fasting Blood Glucose From Normal to High
Percentage of participants with shifts in fasting blood glucose from normal to high (\<100 mg/dL at baseline to \>=126 mg/dL at any post-baseline assessment) were reported.
Time frame: Up to Week 24
Change From Baseline in the Clinical Global Impression-Severity (CGI-S) Scale Score at Weeks 12 and 24
The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S is a 7-point global assessment scale that measures the clinician's impression of the severity of illness exhibited by a participant, rating according to: 1=normal (not at all ill); 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill participants. Higher scores indicate worsening. Negative change in score indicates improvement.
Time frame: Baseline, Weeks 12 and 24
Change From Baseline in the Patient Global Impression Severity (PGI-S) Scale Score at Weeks 12 and 24
The PGI-S is a self-report scale to measure severity of illness (1=none, 2=mild, 3=moderate, 4=severe). Higher score indicates more illness severity. Negative change in score indicates improvement.
Time frame: Baseline, Weeks 12 and 24
Change From Baseline in Quality of Life in Depression Scale (QLDS) Score at Weeks 12 and 24
The QLDS is a disease specific patient-reported outcome (PRO) designed to assess health related quality of life in participants with major depressive disorder (MDD). The instrument has a recall period of "at the present time", contains 34-items with "true"/"not true" response options. Each statement on the QLDS is given a score of "1" (adverse quality of life) or "0" good quality of life. All item scores are summed to give a total score that ranges from 0 (good quality of life) to 34 (very poor quality of life). A higher score indicates a more severe condition. Negative change indicates improvement.
Time frame: Baseline, Weeks 12 and 24
Change From Baseline in Patient Reported Outcomes Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form 8a at Weeks 12 and 24
The PROMIS-SD Short Form 8a subscale consists of a static 8 item questionnaire. It assesses the concepts of sleep initiation (2 items), quality of sleep (3 items), early morning feelings (2 items) and worrying about sleep (1 item). Responses to each of the 8 items range from 1 to 5, and the range of possible summed raw scores is 8 to 40. Higher scores on the PROMIS-SD indicate more of the concept measured (disturbed sleep). Negative change in score indicates improvement.
Time frame: Baseline, Weeks 12 and 24
Change From Baseline in Patient Reported Outcomes Measurement Information System-Sleep Related Impairment (PROMIS-SRI) Short Form 8a at Weeks 12 and 24
The PROMIS-SRI Short Form 8a subscale consists of a static 8 item questionnaire and use five-point likert scale to capture the participant's impressions. It assesses sleep-related impairment over the past 7 days. Responses to each of the 8 items range from 1 (less impairment) to 5 (more impairment), and the range of possible summed raw scores is 8 to 40. Lower scores indicate less sleep related impairment. Negative change in score indicates improvement.
Time frame: Baseline, Weeks 12 and 24
Change From Baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) Score at Weeks 12 and 24
The SMDDS assesses participant-reported symptoms associated with MDD. This 16-item instrument has a 7-day recall period, and participants respond to each question using a rating scale between 0 ("Not at all" or "Never") to 4 ("Extremely" or "Always"). Before summing the items to create a total score, item 11 ("how often did you have a poor appetite") and item 12 ("how often did you over eat") are combined into a single score by selecting the highest severity on either item. The total score is then created by summing the responses on the 15 items. The total score ranges from 0 to 60 with a higher score indicating more severe depressive symptomatology. Negative change in score indicates improvement.
Time frame: Baseline, Weeks 12 and 24
Change From Baseline in Symbol Digit Modalities Test (SDMT) at Weeks 6, 12, and 24
SDMT is a widely used, paper-and-pencil assessment of complex scanning and visual tracking, requiring elements of attention, visuoperceptual processing, working memory, and cognitive/psychomotor speed. The test is viewed as a robust screening test for adult neuropsychological impairment and is sensitive to impairments in cognitive function associated with MDD. The SDMT measured the time to pair abstract symbols with specific numbers. The test included a coding key consisting of 9 abstract symbols, each paired with a number ranging from 1 to 9. Following the key, the participant was presented with randomly ordered symbols and was required to write the number corresponding to each symbol as fast as possible. The number of correct substitutions within 90 seconds was recorded and total score derived from the total number of correct responses with a minimum possible score of 0 and maximum of 110 where high scores indicate better outcome. Positive change in score indicates improvement.
Time frame: Baseline, Weeks 6, 12, and 24
Change From Baseline in Trail Making Test - Part B (TMT-Part B) at Weeks 6, 12, and 24
The TMT-Part B measures divided attention and executive function (tracking and sequencing). The participant is instructed to draw a line to connect a set of 25 consecutively numbered and lettered circles, alternating sequentially between numbers and letters (that is, 1 A 2 B). The participant is instructed to work as quickly as possible while still maintaining accuracy. Score included time (seconds) to completion and number of errors in performing the test which ranges from 0 (no errors) to 25 (more errors), where shorter time and less number of errors indicates better performance. The TMT-Part B is sensitive to cognitive decline associated with MDD. Negative change in score indicates improvement.
Time frame: Baseline, Weeks 6, 12, and 24
Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) at Weeks 6, 12, and 24
The HVLT-R measures performance in verbal memory, learning, and long-term recall in which a list of words is read up to three times. Approximately 20-25 minutes later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score (0 -12); the total number of true-positive errors (0-12); and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. A higher score indicates higher cognition.
Time frame: Baseline, Weeks 6, 12, and 24
Change From Baseline in Salivary Cortisol Levels as Measured at Home Upon Awakening and During the Evening at Weeks 6 and 24
Change from baseline in salivary cortisol levels as measured upon awakening and at home during the evening at Weeks 6 and 24 were reported.
Time frame: Baseline, Weeks 6 and 24
Percentage of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent AEs were AEs with onset during the double-blind treatment phase or that were a consequence of a preexisting condition that worsened since baseline.
Time frame: Up to 24 weeks
Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) and Events of Special Interest
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product. AESIs were significant AEs that were judged to be of special interest because of clinical importance, known or suspected class effects, or based on nonclinical signals. Adverse events of special interest were cataplexy, sleep paralysis, complex, and sleep-related behaviors (parasomnias).
Time frame: Up to 24 weeks
Percentage of Participants With Abnormalities in Vital Sign Parameters
Percentage of participants with abnormalities in vital sign parameters (pulse, supine and standing blood pressure \[systolic and diastolic\], body temperature, and body weight) were reported. Abnormally low values for parameters included pulse (beats per minute)- decrease value from baseline (\>=) 15 to \<=50; Systolic Blood Pressure (BP) (mmHg \[Millimeter of mercury\])- decrease value from baseline \>=20 to \<=90; Diastolic BP- decrease value from baseline \>=15 to \<=50; weight (Kilogram\[Kg\])- decrease from baseline of \>=7%; Body temperature (Celsius \[C\])- \<35.5. Abnormally high values for parameters included pulse- increase value from baseline \>=15 to \>=100; Systolic BP(mmHg)- increase from baseline of \>=20 to \>=180; Diastolic BP- increase value from baseline \>=15 to \>=105; weight(Kg)- increase from baseline of \>=7%; body temperature (C)- \>37.5.
Time frame: Up to 24 weeks
Percentage of Participants With Abnormalities in Electrocardiogram (ECG) Parameters
Percentage of participants with abnormalities in ECG parameters were reported.
Time frame: Up to 24 weeks
Percentage of Participants With Abnormalities in Clinical Laboratory Parameters
Percentage of participants with abnormalities in clinical laboratory parameters were reported.
Time frame: Up to 24 weeks
Percentage of Participants With Sexual Dysfunction as Determined by Arizona Sexual Experiences Scale (ASEX) Total Score
Sexual dysfunction is defined as an ASEX total score of 19 or greater, or a score of 5 or greater on any item, or a score of 4 or greater on any 3 items. ASEX is a five-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Each of the 5 items is rated on a 6-point Likert scale, ranging from 1 to 6. The 5 items are summed to create a total score, ranging from 5 to 30, with the higher scores indicating more sexual dysfunction.
Time frame: Up to Endpoint (Up to 24 weeks)
Percentage of Participants With Clinically Relevant Changes in Extrapyramidal Symptoms Assessed by the Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Score
The ESRS-A is an abbreviated manualized version of the ESRS, a semi-structured interview that rates parkinsonian symptoms, dystonia, dyskinesias, and akathisia over the previous 7 days. The ratings include a motor examination for rigidity, tremor, reduced facial expression or speech, impaired gait/posture, postural instability, and bradykinesia/hypokinesia. Twenty-four individual items are rated on a 6-point scale: 0=Absent, 1=Minimal, 2=Mild, 3=Moderate, 4=Severe, or 5=Extreme. Frequency is included as an index of severity.
Time frame: Up to Endpoint (Up to 24 weeks)
Percentage of Participants With Suicidality Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) Score
C-SSRS is a clinician-rated instrument that reports severity and frequency of suicide-related ideation and behaviors. Suicidal ideation was classified on a 5-item scale: 1 (wish to be dead), 2 (non-specific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 6 (preparatory acts or behavior), 7 (aborted attempt), 8 (interrupted attempt), 9 (actual attempt \[non-fatal\]), and 10 (completed suicide \[only applicable for post baseline\]). Minimum total score 0, maximum total score 10; higher total scores indicate more suicidal ideation and/or suicidal behavior. If no events qualify for score of 1 to 10, score of 0 was assigned (0= "no event that can be assessed on the basis of C-SSRS"). Higher scores indicate greater severity.
Time frame: Up to Endpoint (Up to 24 weeks)
Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC)
Intensity of discontinuation symptoms was assessed (anxiety-nervousness, dysphoric mood/depression, Depersonalization-Derealization, , Diaphoresis, Diarrhea, Difficulty Concentrating, Remember, Dizziness-Lightheadedness, Fatigue-Lethargy-Lack of Energy, Headaches, Increased Acuity Sound Smell Touch, Irritability, Loss of Appetite, Muscle Aches or Stiffness, Nausea-Vomiting, Paresthesias, Poor Coordination, Restlessness-Agitation, Tremor-Tremulousness, Weakness), using the Physician Withdrawal Checklist (PWC-20) administered by a trained clinician/rater. Symptoms are rated on a scale of 0 (no symptom present), 1 (mild), 2 (moderate), and 3 (severe). Total scores range from 0 (no symptom) to 24 (severe symptom) calculated by adding the scores of following 8 items: Nausea-Vomiting, Diarrhea, Poor Coordination, Diaphoresis, Tremor-Tremulousness, Dizziness-Lightheadedness, Increased Acuity Sound Smell Touch, Paresthesias. Higher scores indicates more severe symptoms.
Time frame: Up to 26 weeks
Change From Baseline in MADRS Total Score Over Time
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition.
Time frame: Baseline, Weeks 2, 4, 6, 12, 18, 24
Change From Baseline in MADRS Total Score Over Time, by Mode Dose
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. Negative change in score indicates improvement.
Time frame: Baseline, Weeks 2, 4, 6, 12, 18, 24, and 26
Change From Baseline in MADRS-6 Score Over Time
MADRS-6 is the depression subscale of the full MADRS, including the following 6 items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, pessimistic thoughts. Each item is scored from 0 (absence of symptom) to 6 (severe symptom); the overall score ranges from 0 to 36 which is calculated by adding the scores of all 6 items. Higher scores represent a more severe condition.
Time frame: Baseline, Weeks 2, 4, 6, 12, 18, 24, and 26
| Milestone | Seltorexant | Quetiapine XR |
|---|---|---|
| Started | 54 | 53 |
| Completed | 30 | 27 |
| Not completed | 24 | 26 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Withdrawal by subject | 9 | 3 |
| Withdrew: Lack of efficacy | 1 | 3 |
| Withdrew: Adverse event | 7 | 8 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Non-compliance with study drug | 3 | 6 |
| Withdrew: Other | 1 | 4 |
| Milestone | Seltorexant | Quetiapine XR |
|---|---|---|
| Started | 54 | 52 |
| Completed | 30 | 28 |
| Not completed | 24 | 24 |
| Withdrew: Other | 24 | 24 |
Time to all-cause discontinuation of study drug is defined as the number of days from the first dose of study drug to the last dose of study drug. Participants who completed double-blind treatment were not considered to have discontinued.
| days | Seltorexant | Quetiapine XR |
|---|---|---|
| Time to All-Cause Discontinuation of Study Drug | NA (NA to NA) | NA (NA to NA) |
Remission is defined as Montgomery-Asberg Depression Rating Scale (MADRS) total score of less than or equal to (\<=) 12. A participant was defined as having achieved sustained remission if the MADRS total score was ≤12 at Week 12 and was sustained at Weeks 18 and 24. Participants with missing values at a given time point were imputed as non-evaluable for remission. MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition.
| percentage of participants | Seltorexant | Quetiapine XR |
|---|---|---|
| Percentage of Participants With Sustained Remission up to Week 24 | 13.2 | 19.4 |
A participant was defined as having achieved a sustained response if there was at least a 50% improvement from baseline in the MADRS total score at Week 12, and that response was maintained at Week 18 and Week 24. Participants who did not meet such criterion were considered as non-sustained responders. MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition.
| percentage of participants | Seltorexant | Quetiapine XR |
|---|---|---|
| Percentage of Participants With Sustained Response up to Week 24 | 13.2 | 22.2 |
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. The ISI has 7 questions, each rated on a 5-point Likert scale ranging from 0 to 4. The total score is calculated as the sum of the 7 items ranging from 0 to 28. Higher scores represent a more severe condition.
| score on a scale | Seltorexant | Quetiapine XR |
|---|---|---|
| Baseline ISI score <15 | -10.4 ± 12.68 | -12.8 ± 9.67 |
| Baseline ISI score >=15 | -13.4 ± 10.73 | -17.3 ± 9.70 |
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. The ISI has 7 questions, each rated on a 5-point Likert scale ranging from 0 to 4. The total score is calculated as the sum of the 7 items ranging from 0 to 28. Higher scores represent a more severe condition.
| score on a scale | Seltorexant | Quetiapine XR |
|---|---|---|
| Baseline ISI score <15 | -13.9 ± 16.66 | -16.2 ± 10.46 |
| Baseline ISI score >=15 | -10.3 ± 14.96 | -12.9 ± 11.58 |
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. The ISI has 7 questions, each rated on a 5-point Likert scale ranging from 0 to 4. The total score is calculated as the sum of the 7 items ranging from 0 to 28. Higher scores represent a more severe condition.
| score on a scale | Seltorexant | Quetiapine XR |
|---|---|---|
| Baseline ISI score <15 | -14.3 ± 14.47 | -15.6 ± 8.78 |
| Baseline ISI score >=15 | -13.5 ± 14.32 | -15.4 ± 11.76 |
HAM-A is a 14-item scale designed to measure anxiety in individuals. Each question reflects a symptom of anxiety and physical as well as mental symptoms are represented. Each of the 14-items in the scale is scored on a 5-point scale, ranging from 0 (a complete lack of that symptom) to 4 (a very severe show of anxiety with that symptom). The total score ranges from 0 to 56 which is calculated by adding the scores of all 14 items, where 0-13 indicates normal range, 14-17 indicates mild severity, 18 -24: mild to moderate severity, 25 -30: moderate to severe, and \>=31: severe. Higher score indicates worsening. Negative change in score indicates improvement.
| units on a scale | Seltorexant | Quetiapine XR |
|---|---|---|
| Week 12 | -8.7 ± 6.05 | -6.6 ± 6.75 |
| Week 18 | -8.5 ± 6.66 | -10.0 ± 5.69 |
| Week 24 | -10.9 ± 6.55 | -9.5 ± 7.26 |
Percentage of participants with weight gain of \>=7% of baseline body weight at Week 24 were reported.
| percentage of participants | Seltorexant | Quetiapine XR |
|---|---|---|
| Percentage of Participants With Weight Gain of >=7% of Baseline Body Weight at Week 24 | 4.3 | 8.5 |
Percentage of participants with shifts in triglycerides from normal to high (\<150 milligrams per deciliter \[mg/dL\] at baseline to \>=200 mg/dL at any post-baseline assessment) were reported.
| percentage of participants | Seltorexant | Quetiapine XR |
|---|---|---|
| Percentage of Participants With Shifts in Triglycerides From Normal to High | 7.1 | 13.6 |
Percentage of participants with shifts in triglycerides from borderline to high (\>=150 to \<200 mg/dL at baseline to \>=200 mg/dL at any post-baseline assessment) were reported.
| percentage of participants | Seltorexant | Quetiapine XR |
|---|---|---|
| Percentage of Participants With Shifts in Triglycerides From Borderline to High | 25.0 | 37.5 |
Percentage of participants with shifts in triglycerides from normal to very high (\<150 mg/dL at baseline to \>=500 mg/dL at any post-baseline assessment) were reported.
| percentage of participants | Seltorexant | Quetiapine XR |
|---|---|---|
| Percentage of Participants With Shifts in Triglycerides From Normal to Very High | 0 | 0 |
Percentage of participants with shifts in triglycerides from borderline to very high (\>=150 mg/dL to \<200 mg/dL at baseline to \>=500 mg/dL at any post-baseline assessment) were reported.
| percentage of participants | Seltorexant | Quetiapine XR |
|---|---|---|
| Percentage of Participants With Shifts in Triglycerides From Borderline to Very High | 0 | 0 |
Percentage of participants with shifts in triglycerides from high to very high (\>=200 mg/dL to \<500 mg/dL at baseline to \>=500 mg/dL at any post-baseline assessment) were reported.
| percentage of participants | Seltorexant | Quetiapine XR |
|---|---|---|
| Percentage of Participants With Shifts in Triglycerides From High to Very High | 16.7 | 0 |
Percentage of participants with shifts in fasting blood glucose from normal to borderline (\<100 mg/dL at baseline to between \>=100 and \<126 mg/dL at any post-baseline assessment) were reported.
| percentage of participants | Seltorexant | Quetiapine XR |
|---|---|---|
| Percentage of Participants With Shifts in Fasting Blood Glucose From Normal to Borderline | 38.7 | 36.0 |
Percentage of participants with shifts in fasting blood glucose from borderline to high (\>=100 to \<126 mg/dL at baseline to \>=126 mg/dL at any post-baseline assessment) were reported.
| percentage of participants | Seltorexant | Quetiapine XR |
|---|---|---|
| Percentage of Participants With Shifts in Fasting Blood Glucose From Borderline to High | 9.1 | 25.0 |
Percentage of participants with shifts in fasting blood glucose from normal to high (\<100 mg/dL at baseline to \>=126 mg/dL at any post-baseline assessment) were reported.
| percentage of participants | Seltorexant | Quetiapine XR |
|---|---|---|
| Percentage of Participants With Shifts in Fasting Blood Glucose From Normal to High | 3.2 | 4.0 |
The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S is a 7-point global assessment scale that measures the clinician's impression of the severity of illness exhibited by a participant, rating according to: 1=normal (not at all ill); 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill participants. Higher scores indicate worsening. Negative change in score indicates improvement.
| units on a scale | Seltorexant | Quetiapine XR |
|---|---|---|
| Week 12 | -1.2 ± 1.39 | -1.7 ± 1.23 |
| Week 24 | -1.4 ± 1.65 | -1.7 ± 1.10 |
The PGI-S is a self-report scale to measure severity of illness (1=none, 2=mild, 3=moderate, 4=severe). Higher score indicates more illness severity. Negative change in score indicates improvement.
| units on a scale | Seltorexant | Quetiapine XR |
|---|---|---|
| Week 12 | -1.0 ± 1.07 | -1.1 ± 1.02 |
| Week 24 | -1.2 ± 1.10 | -1.5 ± 1.09 |
The QLDS is a disease specific patient-reported outcome (PRO) designed to assess health related quality of life in participants with major depressive disorder (MDD). The instrument has a recall period of "at the present time", contains 34-items with "true"/"not true" response options. Each statement on the QLDS is given a score of "1" (adverse quality of life) or "0" good quality of life. All item scores are summed to give a total score that ranges from 0 (good quality of life) to 34 (very poor quality of life). A higher score indicates a more severe condition. Negative change indicates improvement.
| units on a scale | Seltorexant | Quetiapine XR |
|---|---|---|
| Week 12 | -8.1 ± 9.20 | -8.3 ± 8.68 |
| Week 24 | -9.5 ± 10.32 | -9.9 ± 10.43 |
The PROMIS-SD Short Form 8a subscale consists of a static 8 item questionnaire. It assesses the concepts of sleep initiation (2 items), quality of sleep (3 items), early morning feelings (2 items) and worrying about sleep (1 item). Responses to each of the 8 items range from 1 to 5, and the range of possible summed raw scores is 8 to 40. Higher scores on the PROMIS-SD indicate more of the concept measured (disturbed sleep). Negative change in score indicates improvement.
| units on a scale | Seltorexant | Quetiapine XR |
|---|---|---|
| Week 12 | -8.22 ± 10.073 | -11.87 ± 10.717 |
| Week 24 | -11.45 ± 11.722 | -12.91 ± 7.878 |
The PROMIS-SRI Short Form 8a subscale consists of a static 8 item questionnaire and use five-point likert scale to capture the participant's impressions. It assesses sleep-related impairment over the past 7 days. Responses to each of the 8 items range from 1 (less impairment) to 5 (more impairment), and the range of possible summed raw scores is 8 to 40. Lower scores indicate less sleep related impairment. Negative change in score indicates improvement.
| units on a scale | Seltorexant | Quetiapine XR |
|---|---|---|
| Week 12 | -7.25 ± 9.449 | -9.09 ± 7.992 |
| Week 24 | -11.02 ± 11.061 | -10.74 ± 6.970 |
The SMDDS assesses participant-reported symptoms associated with MDD. This 16-item instrument has a 7-day recall period, and participants respond to each question using a rating scale between 0 ("Not at all" or "Never") to 4 ("Extremely" or "Always"). Before summing the items to create a total score, item 11 ("how often did you have a poor appetite") and item 12 ("how often did you over eat") are combined into a single score by selecting the highest severity on either item. The total score is then created by summing the responses on the 15 items. The total score ranges from 0 to 60 with a higher score indicating more severe depressive symptomatology. Negative change in score indicates improvement.
| units on a scale | Seltorexant | Quetiapine XR |
|---|---|---|
| Week 12 | -13.9 ± 10.92 | -15.7 ± 11.16 |
| Week 24 | -15.6 ± 13.07 | -19.6 ± 11.59 |
SDMT is a widely used, paper-and-pencil assessment of complex scanning and visual tracking, requiring elements of attention, visuoperceptual processing, working memory, and cognitive/psychomotor speed. The test is viewed as a robust screening test for adult neuropsychological impairment and is sensitive to impairments in cognitive function associated with MDD. The SDMT measured the time to pair abstract symbols with specific numbers. The test included a coding key consisting of 9 abstract symbols, each paired with a number ranging from 1 to 9. Following the key, the participant was presented with randomly ordered symbols and was required to write the number corresponding to each symbol as fast as possible. The number of correct substitutions within 90 seconds was recorded and total score derived from the total number of correct responses with a minimum possible score of 0 and maximum of 110 where high scores indicate better outcome. Positive change in score indicates improvement.
| units on a scale | Seltorexant | Quetiapine XR |
|---|---|---|
| Week 6 | 5.0 ± 14.45 | -2.9 ± 11.72 |
| Week 12 | 5.5 ± 17.61 | 0.1 ± 14.07 |
| Week 24 | 4.7 ± 18.78 | 0.0 ± 9.83 |
The TMT-Part B measures divided attention and executive function (tracking and sequencing). The participant is instructed to draw a line to connect a set of 25 consecutively numbered and lettered circles, alternating sequentially between numbers and letters (that is, 1 A 2 B). The participant is instructed to work as quickly as possible while still maintaining accuracy. Score included time (seconds) to completion and number of errors in performing the test which ranges from 0 (no errors) to 25 (more errors), where shorter time and less number of errors indicates better performance. The TMT-Part B is sensitive to cognitive decline associated with MDD. Negative change in score indicates improvement.
| units on a scale | Seltorexant | Quetiapine XR |
|---|---|---|
| Week 6 | 0.4 ± 3.26 | 0.0 ± 2.59 |
| Week 12 | 0.2 ± 3.39 | 0.6 ± 2.93 |
| Week 24 | 0.5 ± 4.54 | -0.3 ± 1.54 |
The HVLT-R measures performance in verbal memory, learning, and long-term recall in which a list of words is read up to three times. Approximately 20-25 minutes later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score (0 -12); the total number of true-positive errors (0-12); and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. A higher score indicates higher cognition.
| units on a scale | Seltorexant | Quetiapine XR |
|---|---|---|
| Total Recall: Week 6 | 0.6 ± 4.60 | -0.1 ± 5.51 |
| Total Recall: Week 12 | 1.9 ± 5.24 | 1.3 ± 5.25 |
| Total Recall: Week 24 | 2.0 ± 5.22 | 1.4 ± 5.09 |
| Delayed Recall: Week 6 | 0.2 ± 2.07 | 0.6 ± 2.57 |
| Delayed Recall: Week 12 | 0.5 ± 2.54 | 1.0 ± 2.52 |
| Delayed Recall: Week 24 | 1.3 ± 2.74 | 1.4 ± 2.39 |
| Total True-Positive Errors: Week 6 | 0.5 ± 4.21 | -0.4 ± 2.71 |
| Total True-Positive Errors: Week 12 | 0.2 ± 3.99 | -0.1 ± 3.59 |
| Total True-Positive Errors: Week 24 | 0.5 ± 3.03 | -0.7 ± 3.07 |
| Recognition Discrimination Index: Week 6 | 0.8 ± 4.03 | 1.0 ± 3.80 |
| Recognition Discrimination Index: Week 12 | -0.3 ± 4.67 | 0.1 ± 5.29 |
| Recognition Discrimination Index: Week 24 | 0.9 ± 2.91 | -0.3 ± 4.69 |
Change from baseline in salivary cortisol levels as measured upon awakening and at home during the evening at Weeks 6 and 24 were reported.
| nanomoles per liter (nmol/L) | Seltorexant | Quetiapine XR |
|---|---|---|
| Awakening: Week 6 | 1.3 ± 9.07 | -2.8 ± 8.27 |
| Awakening: Week 24 | 1.4 ± 9.42 | -1.7 ± 6.86 |
| Evening: Week 6 | -0.7 ± 4.59 | 0.5 ± 5.96 |
| Evening: Week 24 | 1.4 ± 6.85 | 0.9 ± 2.73 |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent AEs were AEs with onset during the double-blind treatment phase or that were a consequence of a preexisting condition that worsened since baseline.
| percentage of participants | Seltorexant | Quetiapine XR |
|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability | 65.4 | 80.8 |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product. AESIs were significant AEs that were judged to be of special interest because of clinical importance, known or suspected class effects, or based on nonclinical signals. Adverse events of special interest were cataplexy, sleep paralysis, complex, and sleep-related behaviors (parasomnias).
| percentage of participants | Seltorexant | Quetiapine XR |
|---|---|---|
| SAEs | 1.9 | 3.8 |
| AESIs | 13.5 | 5.8 |
Percentage of participants with abnormalities in vital sign parameters (pulse, supine and standing blood pressure \[systolic and diastolic\], body temperature, and body weight) were reported. Abnormally low values for parameters included pulse (beats per minute)- decrease value from baseline (\>=) 15 to \<=50; Systolic Blood Pressure (BP) (mmHg \[Millimeter of mercury\])- decrease value from baseline \>=20 to \<=90; Diastolic BP- decrease value from baseline \>=15 to \<=50; weight (Kilogram\[Kg\])- decrease from baseline of \>=7%; Body temperature (Celsius \[C\])- \<35.5. Abnormally high values for parameters included pulse- increase value from baseline \>=15 to \>=100; Systolic BP(mmHg)- increase from baseline of \>=20 to \>=180; Diastolic BP- increase value from baseline \>=15 to \>=105; weight(Kg)- increase from baseline of \>=7%; body temperature (C)- \>37.5.
| percentage of participants | Seltorexant | Quetiapine XR |
|---|---|---|
| Supine Pulse Rate: Abnormally low | 0 | 2.0 |
| Supine Pulse Rate: Abnormally high | 2.0 | 3.9 |
| Standing Pulse Rate: Abnormally low | 0 | 0 |
| Standing Pulse Rate: Abnormally high | 2.0 | 5.9 |
| Supine Systolic Blood Pressure: Abnormally low | 0 | 0 |
| Supine Systolic Blood Pressure: Abnormally high | 0 | 0 |
| Standing Systolic Blood Pressure: Abnormally low | 0 | 2.0 |
| Standing Systolic Blood Pressure: Abnormally high | 0 | 0 |
| Supine Diastolic Blood Pressure: Abnormally low | 0 | 0 |
| Supine Diastolic Blood Pressure: Abnormally high | 0 | 0 |
| Standing Diastolic Blood Pressure: Abnormally low | 0 | 0 |
| Standing Diastolic Blood Pressure: Abnormally high | 2.0 | 0 |
| Temperature: Abnormally low | 0 | 0 |
| Temperature: Abnormally high | 6.0 | 0 |
| Weight: Abnormally low | 4.3 | 0 |
| Weight: Abnormally high | 4.3 | 8.5 |
Percentage of participants with abnormalities in ECG parameters were reported.
| percentage of participants | Seltorexant | Quetiapine XR |
|---|---|---|
| Percentage of Participants With Abnormalities in Electrocardiogram (ECG) Parameters | 0 | 0 |
Percentage of participants with abnormalities in clinical laboratory parameters were reported.
| percentage of participants | Seltorexant | Quetiapine XR |
|---|---|---|
| Percentage of Participants With Abnormalities in Clinical Laboratory Parameters | 0 | 0 |
Sexual dysfunction is defined as an ASEX total score of 19 or greater, or a score of 5 or greater on any item, or a score of 4 or greater on any 3 items. ASEX is a five-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Each of the 5 items is rated on a 6-point Likert scale, ranging from 1 to 6. The 5 items are summed to create a total score, ranging from 5 to 30, with the higher scores indicating more sexual dysfunction.
| percentage of participants | Seltorexant | Quetiapine XR |
|---|---|---|
| Percentage of Participants With Sexual Dysfunction as Determined by Arizona Sexual Experiences Scale (ASEX) Total Score | 64.3 | 75.6 |
The ESRS-A is an abbreviated manualized version of the ESRS, a semi-structured interview that rates parkinsonian symptoms, dystonia, dyskinesias, and akathisia over the previous 7 days. The ratings include a motor examination for rigidity, tremor, reduced facial expression or speech, impaired gait/posture, postural instability, and bradykinesia/hypokinesia. Twenty-four individual items are rated on a 6-point scale: 0=Absent, 1=Minimal, 2=Mild, 3=Moderate, 4=Severe, or 5=Extreme. Frequency is included as an index of severity.
| percentage of participants | Seltorexant | Quetiapine XR |
|---|---|---|
| Percentage of Participants With Clinically Relevant Changes in Extrapyramidal Symptoms Assessed by the Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Score | 0 | 0 |
C-SSRS is a clinician-rated instrument that reports severity and frequency of suicide-related ideation and behaviors. Suicidal ideation was classified on a 5-item scale: 1 (wish to be dead), 2 (non-specific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 6 (preparatory acts or behavior), 7 (aborted attempt), 8 (interrupted attempt), 9 (actual attempt \[non-fatal\]), and 10 (completed suicide \[only applicable for post baseline\]). Minimum total score 0, maximum total score 10; higher total scores indicate more suicidal ideation and/or suicidal behavior. If no events qualify for score of 1 to 10, score of 0 was assigned (0= "no event that can be assessed on the basis of C-SSRS"). Higher scores indicate greater severity.
| percentage of participants | Seltorexant | Quetiapine XR |
|---|---|---|
| 0=No Event | 100 | 100 |
| 1=Wish to be Dead | 0 | 0 |
| 2 = Non-Specific Active Suicidal Thoughts | 0 | 0 |
| 3 = Suicidal Ideation Without Plan and Intent | 0 | 0 |
| 4 = Suicidal Ideation Intent to Act Without Plan | 0 | 0 |
| 5 = Suicidal Ideation With Plan and Intent | 0 | 0 |
| 6 = Preparatory Acts or Behavior | 0 | 0 |
| 7 = Aborted Attempt | 0 | 0 |
| 8 = Interrupted Attempt | 0 | 0 |
| 9 = Actual Attempt | 0 | 0 |
| 10 = Completed Suicide | 0 | 0 |
Intensity of discontinuation symptoms was assessed (anxiety-nervousness, dysphoric mood/depression, Depersonalization-Derealization, , Diaphoresis, Diarrhea, Difficulty Concentrating, Remember, Dizziness-Lightheadedness, Fatigue-Lethargy-Lack of Energy, Headaches, Increased Acuity Sound Smell Touch, Irritability, Loss of Appetite, Muscle Aches or Stiffness, Nausea-Vomiting, Paresthesias, Poor Coordination, Restlessness-Agitation, Tremor-Tremulousness, Weakness), using the Physician Withdrawal Checklist (PWC-20) administered by a trained clinician/rater. Symptoms are rated on a scale of 0 (no symptom present), 1 (mild), 2 (moderate), and 3 (severe). Total scores range from 0 (no symptom) to 24 (severe symptom) calculated by adding the scores of following 8 items: Nausea-Vomiting, Diarrhea, Poor Coordination, Diaphoresis, Tremor-Tremulousness, Dizziness-Lightheadedness, Increased Acuity Sound Smell Touch, Paresthesias. Higher scores indicates more severe symptoms.
| percentage of participants | Seltorexant | Quetiapine XR |
|---|---|---|
| Anxiety-Nervousness present (Endpoint [DB]) | 75.0 | 33.3 |
| Anxiety-Nervousness present (Follow-up) | 33.3 | 53.6 |
| Depersonalization-Derealization present (Endpoint [DB]) | 0 | 0 |
| Depersonalization-Derealization present (Follow-up) | 6.7 | 0 |
| Diaphoresis present (Endpoint [DB]) | 0 | 0 |
| Diaphoresis present (Follow-up) | 6.7 | 10.7 |
| Diarrhea present (Endpoint [DB]) | 0 | 0 |
| Diarrhea present (Follow-up) | 0 | 14.3 |
| Difficulty Concentrating, Remembering present (Endpoint [DB]) | 0 | 0 |
| Difficulty Concentrating, Remembering present (Follow-up) | 26.7 | 39.3 |
| Dizziness-Lightheadedness present (Endpoint [DB]) | 0 | 33.3 |
| Dizziness-Lightheadedness present (Follow-up) | 23.3 | 85.7 |
| Dysphoric Mood-Depression present (Endpoint [DB]) | 50.0 | 66.7 |
| Dysphoric Mood-Depression present (Follow-up) | 40.0 | 60.7 |
| Fatigue-Lethargy-Lack of Energy present (Endpoint[DB]) | 50.0 | 66.7 |
| Fatigue-Lethargy-Lack of Energy present (Follow-up) | 33.3 | 39.3 |
| Headaches present (Endpoint [DB]) | 0 | 33.3 |
| Headaches present (Follow-up) | 16.7 | 32.1 |
| Increased Acuity for Sound, Smell, Touch, or Pain present (Endpoint [DB]) | 0 | 0 |
| Increased Acuity for Sound, Smell, Touch, or Pain present (Follow-up) | 6.7 | 7.1 |
| Insomnia present (Endpoint [DB]) | 75.0 | 66.7 |
| Insomnia present (Follow-up) | 33.3 | 46.4 |
| Irritability present (Endpoint [DB]) | 75.0 | 66.7 |
| Irritability present (Follow-up) | 23.3 | 25.0 |
| Loss of Appetite present (Endpoint [DB]) | 25.0 | 66.7 |
| Loss of Appetite present (Follow-up) | 10.0 | 21.4 |
| Muscle Aches or Stiffness present (Endpoint [DB]) | 50.0 | 33.3 |
| Muscle Aches or Stiffness present (Follow-up) | 16.7 | 14.3 |
| Nausea-Vomiting present (Endpoint [DB]) | 0 | 0 |
| Nausea-Vomiting present (Follow-up) | 3.3 | 17.9 |
| Paresthesias present (Endpoint [DB]) | 0 | 0 |
| Paresthesias present (Follow-up) | 3.3 | 3.6 |
| Poor Coordination present (Endpoint [DB]) | 25.0 | 33.3 |
| Poor Coordination present (Follow-up) | 10.0 | 85.7 |
| Restlessness-Agitation present (Endpoint [DB]) | 25.0 | 33.3 |
| Restlessness-Agitation present (Follow-up) | 26.7 | 10.7 |
| Tremor-Tremulousness present (Endpoint [DB]) | 0 | 33.3 |
| Tremor-Tremulousness present (Follow-up) | 3.3 | 14.3 |
| Weakness present (Endpoint [DB]) | 25.0 | 33.3 |
| Weakness present (Follow-up) | 3.3 | 14.3 |
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition.
| score on a scale | Seltorexant | Quetiapine XR |
|---|---|---|
| Week 2 | -6.7 ± 9.00 | -6.4 ± 8.00 |
| Week 4 | -8.7 ± 9.71 | -10.8 ± 9.60 |
| Week 6 | -9.9 ± 9.98 | -11.4 ± 9.40 |
| Week 12 | -12.3 ± 11.41 | -15.6 ± 9.80 |
| Week 18 | -11.7 ± 15.48 | -14.1 ± 11.41 |
| Week 24 | -13.8 ± 14.13 | -15.4 ± 10.57 |
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. Negative change in score indicates improvement.
| score on a scale | Seltorexant 20 mg | Seltorexant 40 mg | Quetiapine XR 150 mg | Quetiapine XR 300 mg |
|---|---|---|---|---|
| Week 2 | -7.3 ± 7.28 | -2.4 ± 5.66 | -4.5 ± 5.80 | -3.6 ± 5.49 |
| Week 4 | -7.7 ± 8.05 | -4.4 ± 6.25 | -6.9 ± 6.99 | -6.9 ± 6.79 |
| Week 6 | -9.1 ± 9.26 | -5.2 ± 6.26 | -7.3 ± 5.67 | -7.6 ± 7.82 |
| Week 12 | -11.8 ± 9.34 | -5.3 ± 6.69 | -12.5 ± 6.87 | -9.3 ± 7.99 |
| Week 18 | -12.8 ± 9.98 | -3.8 ± 9.64 | -6.0 ± 8.26 | -10.5 ± 8.61 |
| Week 24 | -14.9 ± 7.93 | -5.2 ± 8.38 | -11.9 ± 6.06 | -9.7 ± 9.53 |
| Week 26 | -16.3 ± 7.52 | -9.3 ± 8.98 | -8.3 ± 7.10 | -8.6 ± 8.45 |
MADRS-6 is the depression subscale of the full MADRS, including the following 6 items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, pessimistic thoughts. Each item is scored from 0 (absence of symptom) to 6 (severe symptom); the overall score ranges from 0 to 36 which is calculated by adding the scores of all 6 items. Higher scores represent a more severe condition.
| score on a scale | Seltorexant | Quetiapine XR |
|---|---|---|
| Week 2 | -4.4 ± 6.76 | -4.1 ± 5.60 |
| Week 4 | -5.8 ± 7.18 | -6.9 ± 6.79 |
| Week 6 | -6.7 ± 7.69 | -7.5 ± 6.95 |
| Week 12 | -7.5 ± 8.18 | -10.4 ± 7.68 |
| Week 18 | -7.2 ± 10.60 | -9.2 ± 8.62 |
| Week 24 | -9.1 ± 9.40 | -10.3 ± 8.59 |
| Week 26 | -9.1 ± 8.97 | -8.4 ± 7.83 |
Collected over Up to 26 weeks for serious and other (non-serious) adverse events and up to 30 weeks for all-cause mortality. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-blind: Seltorexant | 1/52 (1.9%) | 1/52 (1.9%) | 21/52 (40.4%) |
| Double-blind: Quetiapine XR | 0/52 (0%) | 2/52 (3.8%) | 32/52 (61.5%) |
| Follow-up: Seltorexant | 0/52 (0%) | 0/52 (0%) | 1/52 (1.9%) |
| Follow-up: Quetiapine XR | 0/52 (0%) | 0/52 (0%) | 2/52 (3.8%) |
| Event | Double-blind: Seltorexant | Double-blind: Quetiapine XR | Follow-up: Seltorexant | Follow-up: Quetiapine XR |
|---|---|---|---|---|
| Atrial FlutterCardiac disorders | 1/52 | 0/52 | 0/52 | 0/52 |
| Spinal Column StenosisMusculoskeletal and connective tissue disorders | 0/52 | 1/52 | 0/52 | 0/52 |
| Suicide AttemptPsychiatric disorders | 0/52 | 1/52 | 0/52 | 0/52 |
| Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders | 1/52 | 0/52 | 0/52 | 0/52 |
| Event | Double-blind: Seltorexant | Double-blind: Quetiapine XR | Follow-up: Seltorexant | Follow-up: Quetiapine XR |
|---|---|---|---|---|
| Dry MouthGastrointestinal disorders | 3/52 | 13/52 | 0/52 | 0/52 |
| SomnolenceNervous system disorders | 6/52 | 11/52 | 0/52 | 0/52 |
| Abnormal DreamsPsychiatric disorders | 7/52 | 1/52 | 0/52 | 0/52 |
| FatigueGeneral disorders | 2/52 | 4/52 | 0/52 | 0/52 |
| Weight IncreasedInvestigations | 4/52 | 3/52 | 0/52 | 1/52 |
| DiarrhoeaGastrointestinal disorders | 0/52 | 3/52 | 0/52 | 1/52 |
| NauseaGastrointestinal disorders | 0/52 | 3/52 | 0/52 | 0/52 |
| VomitingGastrointestinal disorders | 0/52 | 3/52 | 0/52 | 1/52 |
| BronchitisInfections and infestations | 1/52 | 3/52 | 0/52 | 0/52 |
| HeadacheNervous system disorders | 3/52 | 1/52 | 1/52 | 0/52 |
The safety analysis set included all randomized participants who received at least 1 dose of study drug including the 2 participants who received the potentially defective investigational product (IP).
| Age, Continuous(years) | Seltorexant | Quetiapine XR | Total |
|---|---|---|---|
| Mean | 55.3 ± 9.67 | 53.6 ± 10.83 | 54.5 ± 10.26 |
| Age, Customized(Participants) | Seltorexant | Quetiapine XR | Total |
|---|---|---|---|
| Adults (18-64 years) | 43 | 43 | 86 |
| From 65 to 84 years | 9 | 9 | 18 |
| 85 years and over | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Seltorexant | Quetiapine XR | Total |
|---|---|---|---|
| Female | 34 | 35 | 69 |
| Male | 18 | 17 | 35 |
| Ethnicity (NIH/OMB)(Participants) | Seltorexant | Quetiapine XR | Total |
|---|---|---|---|
| Hispanic or Latino | 17 | 10 | 27 |
| Not Hispanic or Latino | 34 | 41 | 75 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Race (NIH/OMB)(Participants) | Seltorexant | Quetiapine XR | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 2 |
| Black or African American | 14 | 14 | 28 |
| White | 36 | 36 | 72 |
| More than one race | 0 | 2 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Seltorexant | Quetiapine XR | Total |
|---|---|---|---|
| UNITED STATES | 52 | 52 | 104 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2017 to primary completion in Jun 2019, 18 months.
Results were first posted in Aug 2022, 3 years 2 months after primary completion. A results delay was requested in Jun 2020.
Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 18 months is close to that.
Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Seltorexant
Janssen Research & Development, LLC →